1. The Role of CETP in Reverse Cholesterol Transport: Will Its Inhibition Reverse Atherosclerosis?

2. What is the likely mechanism by which HDL-C reduces coronary heart disease?

3. By what mechanism of action are CETP inhibitors (eg, dalcetrapib, anacetrapib) believed to change lipid levels?

4. Infusing HDL Slows Development and Promotes Regression of Atherosclerosis

6. Reverse Cholesterol Transport

7. CETP and Reverse Cholesterol Transport

8. CETP Deficiency: Geneotype and Risk

9. CETP Inhibition and the Effect on Lipoprotein Levels

10. Inhibition of CETP: Effect on HDL Function

11. ILLUMINATE: Torcetrapib in Patients With High Cardiovascular Risk

12. Differential Effects of CETP Inhibitors on HDL Subtypes

13. DEFINE: Effect of Anacetrapib on Lipoprotein(a)

14. TNT: On-Treatment HDL-C Predicts CV Event 5-Year Risk When LDL-C Is < 70 mg/dL

15. Meta-analysis of Nicotinic Acid Trials

16. CETP Inhibitors: Past and Present

17. ILLUMINATE: Protocol-Specified Secondary and Tertiary Outcomes

18. Comparison of CETP Inhibitors

19. Dalcetrapib: Effect on CV Events and Total Vessel Area

20. dal-OUTCOMES: Study Design

21. REVEAL: Randomized Evaluation of the Effects of Anacetrapib Through Lipid Modification

22. Program Summary